STOCK TITAN

[SCHEDULE 13G/A] Compass Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Compass Therapeutics (CMPX) Schedule 13G/A: Tang Capital affiliates and Kevin Tang report shared beneficial ownership of 13,496,208 shares of Compass Therapeutics common stock, representing 9.8% of the outstanding class based on 138,282,498 shares outstanding as of April 28, 2025. The filing states no sole voting or dispositive power; all 13,496,208 shares are held with shared voting and shared dispositive power among Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; and Kevin Tang. The filing certifies the holdings were not acquired to change or influence control of the issuer.

Compass Therapeutics (CMPX) Schedule 13G/A: Affiliate di Tang Capital e Kevin Tang segnalano la titolarità in comune di 13.496.208 azioni ordinarie di Compass Therapeutics, corrispondenti al 9,8% della classe in circolazione su un totale di 138.282.498 azioni in circolazione al 28 aprile 2025. Il deposito indica di avere nessun potere di voto o dispositivo esclusivo; tutte le 13.496.208 azioni sono detenute con potere di voto condiviso e potere dispositivo condiviso tra Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; e Kevin Tang. Il deposito certifica che le partecipazioni non sono state acquisite con l’intento di cambiare o influenzare il controllo dell’emittente.

Compass Therapeutics (CMPX) Schedule 13G/A: Afiliados de Tang Capital y Kevin Tang informan la propiedad compartida de 13.496.208 acciones ordinarias de Compass Therapeutics, que representan el 9,8% de la clase en circulación sobre 138.282.498 acciones en circulación a fecha del 28 de abril de 2025. La presentación indica ningún poder de voto o dispositivo en solitario; las 13.496.208 acciones se mantienen con poder de voto compartido y poder dispositivo compartido entre Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; y Kevin Tang. La presentación certifica que las participaciones no se adquirieron para cambiar o influir en el control del emisor.

Compass Therapeutics (CMPX) Schedule 13G/A: Tang Capital 계열사들과 Kevin Tang은 Compass Therapeutics 보통주 13,496,208주에 대한 공동 실질 소유를 보고했으며, 이는 2025년 4월 28일 기준 발행주식 138,282,498주 중 발행주식의 9.8%에 해당합니다. 제출서류는 단독 의결권 또는 처분권이 없음을 명시하고 있으며; 13,496,208주는 Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; 및 Kevin Tang 간에 의결권 및 처분권이 공동으로 보유되어 있습니다. 제출서는 해당 지분이 발행회사의 지배권을 변경하거나 영향을 미치기 위해 취득된 것이 아님을 증명합니다.

Compass Therapeutics (CMPX) Schedule 13G/A : Des affiliés de Tang Capital et Kevin Tang déclarent la propriété conjointe de 13 496 208 actions ordinaires de Compass Therapeutics, représentant 9,8 % de la catégorie en circulation sur 138 282 498 actions en circulation au 28 avril 2025. Le dépôt indique aucun pouvoir exclusif de vote ou de disposition ; les 13 496 208 actions sont détenues avec pouvoir de vote partagé et pouvoir de disposition partagé entre Tang Capital Management, LLC ; Tang Capital Partners, LP ; Tang Capital Partners International, LP ; Tang Capital Partners III, Inc. ; Tang Capital Partners IV, Inc. ; et Kevin Tang. Le dépôt certifie que ces participations n’ont pas été acquises dans le but de changer ou d’influencer le contrôle de l’émetteur.

Compass Therapeutics (CMPX) Schedule 13G/A: Tang Capital-Tochtergesellschaften und Kevin Tang melden gemeinsamen wirtschaftlichen Besitz von 13.496.208 Aktien der Compass Therapeutics Stammaktien, was 9,8 % der ausstehenden Klasse von 138.282.498 ausstehenden Aktien zum 28. April 2025 entspricht. Die Meldung gibt an, keine alleinige Stimm- oder Verfügungsgewalt zu haben; alle 13.496.208 Aktien werden mit geteilter Stimm- und geteilter Verfügungsgewalt gehalten, und zwar durch Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; und Kevin Tang. Die Meldung bestätigt, dass die Bestände nicht erworben wurden, um die Kontrolle des Emittenten zu ändern oder zu beeinflussen.

Positive
  • Material disclosure of a 9.8% position (13,496,208 shares) provides transparency to the market
  • Clear identification of all reporting persons and their shared voting and dispositive powers
  • Certification included stating shares were not acquired to change or influence control
Negative
  • None.

Insights

TL;DR: Tang Capital group holds a material 9.8% stake in CMPX with shared voting/dispositive power, a notable ownership position for investors to track.

The filing discloses a significant passive stake equal to 13,496,208 shares, representing 9.8% of the company based on the issuer's reported share count. All voting and dispositive authority is shared across multiple Tang entities and Kevin Tang, with zero sole voting or dispositive power reported. This is a standard Section 13 disclosure identifying a large holder; the statement includes a certification that the shares were not acquired to change control.

TL;DR: Ownership structure shows clustered, shared control across related entities and an individual, requiring clear coordination among reporting parties.

The report documents that voting and disposition rights are exercised jointly by affiliated funds, entities and Kevin Tang. Such shared arrangements are common for investment groups and require coordinated disclosures. The statement explicitly classifies types of reporting persons and provides addresses and organizational jurisdictions for each filer, supporting transparency about who exercises shared authority over the 9.8% position.

Compass Therapeutics (CMPX) Schedule 13G/A: Affiliate di Tang Capital e Kevin Tang segnalano la titolarità in comune di 13.496.208 azioni ordinarie di Compass Therapeutics, corrispondenti al 9,8% della classe in circolazione su un totale di 138.282.498 azioni in circolazione al 28 aprile 2025. Il deposito indica di avere nessun potere di voto o dispositivo esclusivo; tutte le 13.496.208 azioni sono detenute con potere di voto condiviso e potere dispositivo condiviso tra Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; e Kevin Tang. Il deposito certifica che le partecipazioni non sono state acquisite con l’intento di cambiare o influenzare il controllo dell’emittente.

Compass Therapeutics (CMPX) Schedule 13G/A: Afiliados de Tang Capital y Kevin Tang informan la propiedad compartida de 13.496.208 acciones ordinarias de Compass Therapeutics, que representan el 9,8% de la clase en circulación sobre 138.282.498 acciones en circulación a fecha del 28 de abril de 2025. La presentación indica ningún poder de voto o dispositivo en solitario; las 13.496.208 acciones se mantienen con poder de voto compartido y poder dispositivo compartido entre Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; y Kevin Tang. La presentación certifica que las participaciones no se adquirieron para cambiar o influir en el control del emisor.

Compass Therapeutics (CMPX) Schedule 13G/A: Tang Capital 계열사들과 Kevin Tang은 Compass Therapeutics 보통주 13,496,208주에 대한 공동 실질 소유를 보고했으며, 이는 2025년 4월 28일 기준 발행주식 138,282,498주 중 발행주식의 9.8%에 해당합니다. 제출서류는 단독 의결권 또는 처분권이 없음을 명시하고 있으며; 13,496,208주는 Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; 및 Kevin Tang 간에 의결권 및 처분권이 공동으로 보유되어 있습니다. 제출서는 해당 지분이 발행회사의 지배권을 변경하거나 영향을 미치기 위해 취득된 것이 아님을 증명합니다.

Compass Therapeutics (CMPX) Schedule 13G/A : Des affiliés de Tang Capital et Kevin Tang déclarent la propriété conjointe de 13 496 208 actions ordinaires de Compass Therapeutics, représentant 9,8 % de la catégorie en circulation sur 138 282 498 actions en circulation au 28 avril 2025. Le dépôt indique aucun pouvoir exclusif de vote ou de disposition ; les 13 496 208 actions sont détenues avec pouvoir de vote partagé et pouvoir de disposition partagé entre Tang Capital Management, LLC ; Tang Capital Partners, LP ; Tang Capital Partners International, LP ; Tang Capital Partners III, Inc. ; Tang Capital Partners IV, Inc. ; et Kevin Tang. Le dépôt certifie que ces participations n’ont pas été acquises dans le but de changer ou d’influencer le contrôle de l’émetteur.

Compass Therapeutics (CMPX) Schedule 13G/A: Tang Capital-Tochtergesellschaften und Kevin Tang melden gemeinsamen wirtschaftlichen Besitz von 13.496.208 Aktien der Compass Therapeutics Stammaktien, was 9,8 % der ausstehenden Klasse von 138.282.498 ausstehenden Aktien zum 28. April 2025 entspricht. Die Meldung gibt an, keine alleinige Stimm- oder Verfügungsgewalt zu haben; alle 13.496.208 Aktien werden mit geteilter Stimm- und geteilter Verfügungsgewalt gehalten, und zwar durch Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; und Kevin Tang. Die Meldung bestätigt, dass die Bestände nicht erworben wurden, um die Kontrolle des Emittenten zu ändern oder zu beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Tang Capital Management, LLC ("TCM") shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), Tang Capital Partners III, Inc ("TCP III"), Tang Capital Partners IV, Inc. ("TCP IV") and Kevin Tang. The percentages used herein are based on 138,282,498 shares of Common Stock outstanding as of April 28, 2025, as set forth in the Issuer's Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on May 8, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, TCP III, TCP IV and TCM.


SCHEDULE 13G




Comment for Type of Reporting Person: TCP shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G




Comment for Type of Reporting Person: TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G




Comment for Type of Reporting Person: TCP III shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G




Comment for Type of Reporting Person: TCP IV shares voting and dispositive power over such shares with TCM and Kevin Tang.


SCHEDULE 13G



TANG CAPITAL MANAGEMENT, LLC
Signature:/s/ Kevin Tang
Name/Title:Manager
Date:08/14/2025
KEVIN TANG
Signature:/s/ Kevin Tang
Name/Title:Self
Date:08/14/2025
TANG CAPITAL PARTNERS, LP
Signature:/s/ Kevin Tang
Name/Title:Manager, Tang Capital Management, LLC, General Partner
Date:08/14/2025
TANG CAPITAL PARTNERS INTERNATIONAL, LP
Signature:/s/ Kevin Tang
Name/Title:Manager, Tang Capital Management, LLC, General Partner
Date:08/14/2025
TANG CAPITAL PARTNERS III, INC
Signature:/s/ Kevin Tang
Name/Title:Chief Executive Officer
Date:08/14/2025
TANG CAPITAL PARTNERS IV, INC
Signature:/s/ Kevin Tang
Name/Title:Chief Executive Officer
Date:08/14/2025

FAQ

How many Compass Therapeutics (CMPX) shares does Tang Capital report owning?

The filing reports 13,496,208 shares beneficially owned by Tang Capital-related parties.

What percentage of CMPX does the reported position represent?

The reported position represents 9.8% of Compass Therapeutics' common stock based on 138,282,498 shares outstanding as of April 28, 2025.

Do any of the reporting persons have sole voting or dispositive power?

No; the filing states 0 shares of sole voting power and 0 shares of sole dispositive power, and all 13,496,208 shares are held with shared voting and dispositive power.

Which entities and individuals are listed as reporting persons in the Schedule 13G/A?

The filers are Tang Capital Management, LLC; Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; Tang Capital Partners IV, Inc.; and Kevin Tang.

Does the filing state the shares were acquired to influence control of CMPX?

The certification in the filing states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
Compass Therapeutics Inc

NASDAQ:CMPX

CMPX Rankings

CMPX Latest News

CMPX Latest SEC Filings

CMPX Stock Data

428.68M
101.95M
14.16%
67.97%
5.67%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON